Pay in 4 interest-free payments of $8.00 Learn more
Ships within 48 hours · Estimated delivery Jul 29 - Aug 3
NVP-TAE 684
J Pediatr Hematol Oncol
Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
It showed 60 fold selectivity against EZH1
The effect of adjuvant dimethylenastron
MLN-9708 - CAS# 1239908-20-3 60262 NVP-TAE 684MLN 9708, also known as ixazomib citrate, CAS No. 1239908 20 3, is a prodrug of Ixazomib (MMLN 2238). MLN 9708 is an orally bioavailable second generation proteasome inhibitor (PI) with potential antineoplastic activity. MLN 9708, after hydrolyzing to pharmacologically active MLN2238 (ixazomib), is a next generation proteasome inhibitor with demonstrated preclinical and clinical antimyeloma activity. MLN 9708, compared with bortezomib, has improved